Patient-reported outcomes Recording and evaluating patient-reported endpoints

Checkpoint inhibitors are increasingly used as mono- or combination therapy in the treatment of metastatic cancer. Patient-reported outcomes can capture the subjective experience and thus also help in the choice of therapy. This article is based on recent guidelines and a selective literature search. Combination therapy with checkpoint inhibitors often improves overall survival. In addition, there may be a positive impact on the general condition and tumor-related symptoms of the patient. In order to assess how this therapeutic success is evaluated by the patients themselves, the determination of the health-related quality of life (HRQOL) is of great importance. Despite standardized evaluation, not all significant differences achieve clinical meaning. For a better classification, the definition of the minimal important difference (MID) is therefore useful. Instruments for recording quality of life allow the subjective assessment of treatment effects. Cut-off values help to assess clinically relevant differences.